Excellence in Dermatology™
Excellence in Dermatologic Surgery™
Excellence in Medical Dermatology™
Excellence in Dermatopathology™

U051 - Hedgehog Inhibitor Therapy for BCC: An Academic and a Private Practice Perspective

Sunday, February 18; 7:00 AM - 8:00 AM

Learning Objectives

Following this course, the attendee should be able to:

  • Summarize the peer reviewed literature of the use of Hedgehog pathway inhibitors.
  • Identify practice gaps to implementation of Hedgehog therapy
  • Recognize important side effect management


Hedgehog (Hh) pathway inhibitors, also called smoothened inhibitors, include vismodegib and sonidegib. They have an important role in complicated BCC tumors. We will review relevant literature and share the perspective and experience of our patient care in both a private practice and academics setting and discuss emerging topics including management of drug-resistant tumors. This activity has been approved by the American Board of Dermatology (ABD) for up to 10 MOC Component 2 Self-Assessment points. For more information about MOC, please visit the ABD website at www.abderm.org.


  • Chang, Anne Lynn S., MD: Galderma Laboratories, L.P. – I(Grants/Research Funding); Genentech, Inc. – I(Grants/Research Funding); Merck & Co., Inc – I(Grants/Research Funding); Novartis Pharmaceuticals Corp. – I(Grants/Research Funding); Nuskin – I(Grants/Research Funding);
  • Strasswimmer, John, MD, PhD: Genentech, Inc. – SP(H); La Roche-Posay Laboratorie Pharmaceutique – Independent Contractor(Grants/Research Funding); Sun Pharmaceutical Industries Ltd. – SP(H);
Sunday, February 18
7:00 AM
All faculty / Hedgehog Inhibitor Therapy for BCC: An Academic and a Private Practice Perspective
Event Details
  • Date
    Sunday, February 18
  • Time
    7:00 AM - 8:00 AM
  • Location
    Room 24B
  • CME Credits
  • Type
  • John Strasswimmer, MD, PhD, FAAD
  • Anne Lynn S. Chang, MD, FAAD